BAM15

BAM15 is a synthetic, mitochondrially targeted small molecule that acts as a selective mitochondrial uncoupler. It disrupts the coupling between electron transport and ATP synthesis in the inner mitochondrial membrane by increasing proton permeability, dissipating the proton gradient, and uncoupling the electron transport chain from ATP synthesis. This leads to increased mitochondrial respiration, energy expenditure, and metabolic activity[1][3][6]. BAM15 activates key signaling pathways such as AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), promoting glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and oxidative metabolism[6]. Preclinical studies have shown that BAM15 reduces body fat mass in mice without affecting food intake or body temperature[4], improves glycemic control independent of weight loss[3], decreases hepatic fat accumulation[2], reduces inflammatory lipids and oxidative stress[8], protects against diet-induced obesity[3][5], reverses insulin resistance in diabetes models[8], mitigates non-alcoholic fatty liver disease progression[5][8], provides protection against sepsis-induced acute kidney injury (AKI)[7] and may offer cardioprotective effects. The compound demonstrates high oral bioavailability in animal models with minimal adverse effects reported to date; however, its development is still preclinical with no approved human use yet. Developers: Virginia Tech Pennington Biomedical Research Center